Vann Equity Management’s AstraZeneca AZN Stock Holding History

Vann Equity Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Buy	1,236 +16	+1%	+$3.01K	0.14%	151
2026 Q1	$241K	Buy	+1,220	New	+$235K	0.17%	140

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vann Equity Management's AZN Position: Q2 2026 in Review

Vann Equity Management increased its AstraZeneca (AZN) stake by 1.3% in Q2 2026, buying an estimated $3.01K and bringing the position to 1,236 shares worth $234K. The position accounts for 0.14% of the portfolio, ranked #151.

Vann Equity Management first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $241K in Q1 2026. 1,481 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Vann Equity Management held 1,236 shares of AstraZeneca worth $234K as of Q2 2026.
Vann Equity Management bought 16 AstraZeneca shares in Q2 2026, an estimated $3.01K.
AstraZeneca made up 0.14% of Vann Equity Management's portfolio in Q2 2026, its #151 holding.
Vann Equity Management first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
Vann Equity Management's AstraZeneca position peaked at $241K in Q1 2026.
1,481 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Vann Equity Management's 13F filing for Q2 2026, filed 5 Aug 2026.